Eli Lilly & Co. 10-K Summary (Fiscal Year Ended Dec 31, 2000)
Business Context and Reporting Period
This Form 10-K covers the fiscal year ended December 31, 2000, for Eli Lilly and Company, an Indiana corporation celebrating its 125th year of business. The Company operates in a single significant business segment: pharmaceutical products. While it maintains an animal health business, operations in this segment are not material to the financial statements. Eli Lilly discovers, develops, manufactures, and sells products in approximately 160 countries, with major therapeutic areas including neuroscience, endocrine, anti-infectives, cardiovascular, and oncology.
Key Financial Metrics
Revenue, Profit, Cash Flow, Margins, Debt, and Liquidity: The filing text incorporates the Consolidated Statements of Income, Balance Sheets, and Cash Flows by reference to the 2000 Annual Report (Exhibit 13) and does not provide specific numerical values for revenue, net income, cash flow, margins, or total debt within this document. Consequently, specific financial performance metrics cannot be extracted from the provided text.
Research and Development (R&D): The Company expended $2.02 billion on research and development activities in 2000, compared to $1.78 billion in 1999 and $1.74 billion in 1998.
Market Data: As of February 15, 2001, the aggregate market value of voting stock held by non-affiliates was approximately $72.23 billion. The number of common shares outstanding was 1,125,533,066.
Material Changes and Operational Highlights
- Patent Expirations: The U.S. compound patent for Prozac expired in February 2001. A method-of-use patent expiring in December 2003 was ruled invalid by the U.S. Court of Appeals for the Federal Circuit, though the Company is appealing. The Company expects a very substantial decline in U.S. Prozac sales in the twelve months following the entry of generic competitors (anticipated around August 3, 2001).
- Regulatory Action: In March 2001, the FDA issued a warning letter regarding deviations from current Good Manufacturing Practices (cGMP) at a facility involved in a pending application for a rapid-acting intramuscular formulation of Zyprexa. The Company does not currently expect a material financial impact but is implementing corrective measures.
- Legal Proceedings: The Company is a defendant in product liability litigation involving DES and Prozac. Additionally, the FTC commenced a non-public antitrust investigation in 1996 regarding rebates to managed-care organizations.
- Executive Changes: Mitchell E. Daniels, Jr., resigned in January 2001 to head the White House Office of Management and Budget. John C. Lechleiter was appointed Executive Vice President, Pharmaceutical Products and Corporate Development in January 2001.
Guidance, Outlook, and Risks
Outlook: Management anticipates a very substantial decline in U.S. Prozac sales in 2001 due to generic competition. The Company expects governments inside and outside the U.S. to continue proposing measures to contain health care costs, which could adversely affect business.
Risks and Contingencies:
- Intellectual Property: Loss of patent protection for key products (Prozac, Axid, Zyprexa, Humalog, ReoPro, Gemzar, Evista, Actos) poses a significant risk. Generic competition typically results in intense price competition.
- Regulatory Environment: Extensive government regulation governs testing, approval, and marketing. New legislation regarding the reimportation of prescription drugs was signed in October 2000, though its implementation depends on further regulatory demonstrations.
- Competition: The pharmaceutical market is highly competitive. Success depends on the ability to discover and develop innovative products and to manufacture them efficiently.
- Legal: Outcomes of pending patent litigation (specifically regarding Prozac) and product liability suits could materially affect results of operations in any one accounting period.
Investor Verification Checklist
- Verify the specific financial impact of the Prozac patent expiration and generic competition on 2001 revenue projections in the "Financial Expectations for 2001" section of the Annual Report.
- Review the status of the appeal regarding the invalidation of the Prozac 2003 method-of-use patent.
- Confirm the resolution timeline and potential financial impact of the FDA warning letter regarding cGMP deficiencies at the Zyprexa manufacturing facility.
- Examine the "Selected Financial Data" in the Annual Report for specific revenue, profit, and cash flow figures not included in this 10-K text.
- Assess the potential impact of the FTC antitrust investigation on future rebate and discount strategies.